Kura Oncology Statistics

Total Valuation

Kura Oncology has a market cap or net worth of $1.45 billion. The enterprise value is $1.04 billion.

Market Cap	1.45B
Enterprise Value	1.04B

Important Dates

The next estimated earnings date is Wednesday, May 8, 2024, after market close.

Earnings Date	May 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Kura Oncology has 76.14 million shares outstanding. The number of shares has increased by 9.31% in one year.

Shares Outstanding	76.14M
Shares Change (YoY)	+9.31%
Shares Change (QoQ)	+0.18%
Owned by Insiders (%)	1.08%
Owned by Institutions (%)	105.93%
Float	49.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.64
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.26, with a Debt / Equity ratio of 0.04.

Current Ratio	12.26
Quick Ratio	n/a
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-97.54

Financial Efficiency

Return on equity (ROE) is -36.30% and return on invested capital (ROIC) is -40.00%.

Return on Equity (ROE)	-36.30%
Return on Assets (ROA)	-33.10%
Return on Capital (ROIC)	-40.00%
Revenue Per Employee	n/a
Profits Per Employee	-$1.07M
Employee Count	142
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +77.07% in the last 52 weeks. The beta is 0.87, so Kura Oncology's price volatility has been lower than the market average.

Beta (1Y)	0.87
52-Week Price Change	+77.07%
50-Day Moving Average	20.63
200-Day Moving Average	13.77
Relative Strength Index (RSI)	44.75
Average Volume (30 Days)	1,159,187

Short Selling Information

The latest short interest is 10.12 million, so 13.29% of the outstanding shares have been sold short.

Short Interest	10.12M
Short Previous Month	10.41M
Short % of Shares Out	13.29%
Short % of Float	20.31%
Short Ratio (days to cover)	11.66

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-165.80M
Pretax Income	-152.63M
Net Income	-152.63M
EBITDA	-150.23M
EBIT	-151.08M
Earnings Per Share (EPS)	-$2.08

Full Income Statement

Balance Sheet

The company has $423.96 million in cash and $17.20 million in debt, giving a net cash position of $406.76 million or $5.34 per share.

Cash & Cash Equivalents	423.96M
Total Debt	17.20M
Net Cash	406.76M
Net Cash Per Share	$5.34
Equity / Book Value	397.27M
Book Value Per Share	5.22
Working Capital	397.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$124.82 million and capital expenditures -$168,000, giving a free cash flow of -$124.99 million.

Operating Cash Flow	-124.82M
Capital Expenditures	-168,000
Free Cash Flow	-124.99M
FCF Per Share	-$1.71

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kura Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.31%
Shareholder Yield	-9.31%
Earnings Yield	-10.55%
FCF Yield	-8.64%

Analyst Forecast

The average price target for Kura Oncology is $28.05, which is 47.63% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$28.05
Price Target Difference	47.63%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1